NurPhoto via NurPhoto via Getty Images
Antibodies induced by Moderna’s Covid vaccine persist 6 months after the second dose of the vaccine (mRNA-1273). The pharmaceutical company communicates it. The data are published in the Letter to Editor of the New England Journal of Medicine. The most recent results, Moderna says, indicate that mRNA-1273-activated antibodies are present 6 months after the second dose. The study analyzed 33 healthy adults who participated in the NIH-led phase 1 study of Moderna’s Covid-19 vaccine. Studies are ongoing that monitor immune responses beyond 6 months.
“We are pleased that these new data show the persistence of antibodies for 6 months after the second dose of our Covid-19 vaccine,” said Stéphane Bancel, CEO of Moderna. This, he stressed, “gives us further confidence in the protection offered by our vaccine. We remain committed to continuing to tackle the Covid-19 pandemic ″.
Moderna, the same company states in a statement, “is also pursuing a clinical development strategy against emerging variants”. In addition, NIAID, part of the National Institutes of Health (NIH), “will conduct a Phase 1 clinical trial to evaluate monovalent and multivalent modified mRNA-1273 vaccines as a primary series in newborn individuals and as a booster vaccine in those
previously vaccinated with mRNA-1273 ″.